Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-555739 in PGD2-induced nasal airway resistance in healthy adults
2008-006787-11Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asapiprant in allergic rhinitis (AR) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Proportion of subjects with higher PD75 on S-555739 vs placebo (Day 8). Started Jan 2009; status: completed.
02
Drugs
asapiprant
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2008-006787-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006787-11.